| Description |
1 online resource (xx, 554 pages) : illustrations (some color) |
| Series |
Cambridge medicine (Series)
|
| Contents |
Cover -- Half-title page -- Title page -- Dedication page -- Copyright page -- Contents -- List of Contributors -- Foreword -- Acknowledgments -- Section 1: Advancing Alzheimer's Disease Therapies in a Collaborative Science Ecosystem -- 1 Alzheimer's Disease Drug Development: A Research and Development Ecosystem -- 2 Drug Development for Alzheimer's Disease: An Historical Perspective -- 3 Alzheimer's Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing -- 4 The Harrington Discovery Institute and Alzheimer's Disease Drug Development -- 5 Repurposed Agents in Alzheimer's Disease Drug Development -- 6 Artificial Intelligence in Alzheimer's Drug Discovery -- Section 2: Non-clinical Assessment of Alzheimer's Disease Candidate Drugs -- 7 Role of Animal Models in Alzheimer's Disease Drug Development -- 8 Use of Induced Pluripotent Stem Cell-Derived Neuronal Disease Models from Patients with Familial Early-Onset Alzheimer's Disease in Drug Discovery -- 9 Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer's Disease Drug Discovery -- 10 Biobanking and Biomarkers in the Alzheimer's Disease Drug-Development Ecosystem -- Section 3: Alzheimer's Disease Clinical Trials -- 11 Phase 1 Trials in Alzheimer's Disease Drug Development -- 12 The Importance of Phase 2 in Drug Development for Alzheimer's Disease -- 13 Alzheimer's Disease Drug Development in Pharmaceutical Companies -- 14 Trial Site Infrastructure and Management: Importance to Alzheimer's Disease Drug Development -- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development -- 16 The European Prevention of Alzheimer's Disease Program: A Public-Private Partnership to Facilitate the Secondary Prevention of Alzheimer's Disease Dementia |
|
17 The Global Alzheimer's Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials -- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration -- 19 Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials -- 20 Alzheimer's Disease Trial Recruitment and Diversifying Trial Populations -- 21 The Role of Online Registries in Accelerating Alzheimer's Disease Drug Development -- 22 Data Safety Monitoring Boards in Alzheimer's Disease Trials -- 23 Globalization of Alzheimer's Disease Clinical Trials -- 24 The Use and Development of Clinical Measures of Alzheimer's Disease Trials -- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer's Disease Clinical Trials -- 26 Expanded Access and Compassionate Use in Alzheimer's Disease Drug Development -- 27 The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program -- 28 The Role of Regulatory Agencies in Alzheimer's Disease Drug Development -- 29 Alzheimer's Disease Clinical Trial Study Partners -- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment? -- 31 Best Practices for Clinical Trials during COVID-19 -- Section 4: Imaging and Biomarker Development in Alzheimer's Disease Drug Discovery -- 32 Development of Fluid Biomarkers for Alzheimer's Disease -- 33 Brain Imaging for Alzheimer's Disease Clinical Trials -- 34 Sharing of Alzheimer's Disease Research Data in the Global Alzheimer's Association Interactive Network -- 35 Pharmacogenetics in Alzheimer's Disease Drug Discovery and Personalized Treatment -- 36 The Role of Electroencephalography in Alzheimer's Disease Drug Development -- Section 5: Academic Drug-Development Programs -- 37 Institutional Review Boards and Oversight of Alzheimer's Disease Trials |
|
38 SPARKing Drug Development for Alzheimer's Disease in Academia -- 39 The Role of Professional Associations and Patient Advocacy in Advancing Alzheimer's Disease Drug Development -- Section 6: Public-Private Partnerships in Alzheimer's Disease Drug Development -- 40 Alzheimer's Disease Neuroimaging Initiative -- Section 7: Funding and Financing Alzheimer's Disease Drug Development -- 41 Financing Alzheimer's Disease Drug Development -- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development -- 43 Alzheimer's Association Funding and Policy for Alzheimer's Disease Drug Development -- 44 The Role of Philanthropy in Alzheimer's Disease Therapeutic Development -- 45 National Institute on Aging's Alzheimer's Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer's Disease and Related Dementias -- 46 Alzheimer's Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study -- 47 Introduction to Venture Capital in Alzheimer's Disease Drug Development -- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer's Disease Drug Development -- Index |
| Summary |
"Alzheimer's Disease Drug Development: A Research and Development Ecosystem captures the complexity of Alzheimer's disease (AD) drug develop and provides a comprehensive set of perspectives from the many stakeholders involved in discovering and developing new therapies for AD. There is no greater unmet therapeutic need for humanity than effective therapies for brain disorders. The suffering caused by these conditions and other neurodegenerative disorders is overwhelming and is burdened with substantial stigma. Therefore, I have devoted my professional life to changing the way brain disorders such as schizophrenia, depression, AD, among others are not only treated, but also viewed by society. From my time with the National Institutes of Health, Janssen and Johnson & Johnson where I serve as the Global Head of Science for Minds, my colleagues and I recognize there is still much to uncover about brain disorders due to the rich complexity of the brain and the challenges in accessing it. But that is not a reason to stop - especially as we enter the golden age of neuroscience, driven largely by scientific breakthroughs and accelerated regulatory pathways"-- Provided by publisher |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record and CIP data provided by publisher; resource not viewed |
| Subject |
Alzheimer's disease.
|
|
Drug development.
|
|
Drugs -- Research.
|
|
Alzheimer's disease -- Treatment
|
|
Alzheimer Disease
|
|
Alzheimer's disease
|
|
Alzheimer's disease -- Treatment
|
|
Drug development
|
|
Drugs -- Research
|
| Form |
Electronic book
|
| Author |
Cummings, Jeffrey L., 1948- editor.
|
|
Kinney, Jefferson W., 1971- editor
|
|
Fillit, Howard, editor.
|
| LC no. |
2021025986 |
| ISBN |
9781108975759 |
|
1108975755 |
|
